Some scientific and organizational challenges in cancer immunology

Annals of the New York Academy of Sciences

Volumn 1174, Issue , 2009, Pages 1-5

  Steinman, Ralph M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Cancer immunity; Dendritic cells; Vaccine

Indexed keywords

CANCER VACCINE; CYCLIN B1; MESOTHELIN; RITUXIMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; CELL SURFACE RECEPTOR; DEC 205 RECEPTOR; DEC-205 RECEPTOR; LECTIN; LEUKOCYTE ANTIGEN;

CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER RADIOTHERAPY; CONFERENCE PAPER; DENDRITIC CELL; GLIOMA; HUMAN; NATURAL KILLER T CELL; EDITORIAL; IMMUNITY; IMMUNOLOGY; NEOPLASM; T LYMPHOCYTE;

ANTIGENS, CD; CANCER VACCINES; DENDRITIC CELLS; GLIOMA; HUMANS; IMMUNITY; LECTINS, C-TYPE; NEOPLASMS; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES;

EID: 70350506277     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05060.x     Document Type: Conference Paper

References (16)

1. Wang, B., J.M.Y. Kuroiwa, L.-Z. He, et al. 2009. The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells. Ann. N. T. Acad Sci. doi:10.1111/j.1749-6632.2009.04933.x.
2. Okada, H. 2009. Brain tumor immunotherapy with type-1 polarizing strategies. Ann. N. Y. Acad. Sci. doi: 10.1111/j.1749-6632.2009.04932.x.
3. Banchereau, J., E. Klechevsky, N. Schmitt, et al. 2009. Harnessing human dendritic cell subsets to design novel vaccines. Ann. N. Y. Acad. Sci. doi: 10.1111/j.1749-6632.2009.04999.x.
4. Mulé J.J. 2009. Dendritic cell-based vaccines for pancreatic cancer and melanoma. Ann. N. Y. Acad Sci. doi: 10.1111/j.1749-6632.2009.04936.x.
5. Mann, D.L., C.M. Celluzzi, K.G. Hankey, et al. 2009. Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers. Ann. N. Y. Acad. Sci. doi: 10.1111/j.1749-6632.2009.04934.x.
6. Locher, C., S. Rusakiewicz, A. Tesnière, et al. 2009. Witch hunt against tumor cells enhanced by dendritic cells. Ann. N. Y. Acad. Sci. doi: 10.1111/j.1749-6632.2009.04940.x.
7. Neparidze, N. & M.V. Dhodapkar. 2009. Harnessing CD1d-restricted T cells toward antitumor immunity in humans. Ann. N. Y. Acad. Sci. doi:10.1111/j.1749-6632.2009.04931.x.
8. Vella, L.A., M. Yu, A.B. Phillips & O.J. Finn. 2009. Immunity against cyclin Bl tumor antigen delays development of spontaneous cyclin Bl-positive tumors in p53-/- mice. Ann. N. Y. Acad. Sci. doi: 10.1111/j.1749-6632.2009. 04941.x.
9. Dranoff, G. 2009. Targets of protective tumor immunity. Ann. N. Y. Acad. Sci. doi: 10.1111/j.1749-6632.2009.04938.x.
10. Dang, Y. & M.L. Disis. 2009. Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer. Ann. N. Y. Acad. Sci. doi: 10.1111/j.1749-6632.2009.04937.x.
11. Palucka K., H. Ueno, J. Fay & J Banchereau. 2009. Harnessing dendritic cells to generate cancer vaccines. Ann. N. Y. Acad. Sci. doi:10.1111/j.1749-6632.2009.05000.x.
12. Rech, A.J. & R.H. Vonderheide. 2009. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann. N. Y. Acad. Sci. doi: 10.1111/j.1749-6632. 2009.04939.x.
13. Berinstein, N.L. 2009. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model. Ann. N. Y. Acad. Sci. doi: 10.1111/j.1749-6632.2009.04935.x.
14. Jaiswal, S. & I.L. Weissman. 2009. Hematopoietic stem and progenitor cells and the inflammatory response. Ann. N. Y. Acad. Sci doi:10.1111/j.1749- 6632.2009.04930.x.
15. Kolata, G. 2009. Advances elusive in the drive to cure cancer. New Tork Times, 23 April. http://www. nytimes.com/2009/04/24/health/policy/24cancer. html?ref=research.
16. Kolata, G. 2009. Grant system leads cancer researchers to play it safe. New Tork Times, 27, June. http://www.nytimes.com/2009/06/28/health/research/ 28cancer.html?scp=25&sq=kolata&st=cse.